Invention Grant
- Patent Title: Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
-
Application No.: US16837356Application Date: 2020-04-01
-
Publication No.: US11919946B2Publication Date: 2024-03-05
- Inventor: Michael C. Milone , Enxiu Wang
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania
- Applicant Address: CH PA Basel
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel; US PA Philadelphia
- Agency: K&L Gates LLP
- The original application number of the division: US15658115 2017.07.24
- Main IPC: C07K16/18
- IPC: C07K16/18 ; C07K14/705 ; C07K14/735

Abstract:
The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
Public/Granted literature
- US20210079073A1 TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY Public/Granted day:2021-03-18
Information query